These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 6508478)
41. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782 [TBL] [Abstract][Full Text] [Related]
42. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Jackson JA; Jankovic J; Ford J Ann Neurol; 1983 Mar; 13(3):273-8. PubMed ID: 6847139 [TBL] [Abstract][Full Text] [Related]
43. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease]. de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286 [TBL] [Abstract][Full Text] [Related]
44. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122 [TBL] [Abstract][Full Text] [Related]
45. [Bromocriptine - various pharmacological properties and indications for use]. Jeske W Pol Tyg Lek; 1982 Jul; 37(22):653-6. PubMed ID: 7177958 [No Abstract] [Full Text] [Related]
46. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease. Anglès A; Bagheri H; Saivin S; Montastruc JL Therapie; 2002; 57(4):408-10. PubMed ID: 12422563 [No Abstract] [Full Text] [Related]
53. [Naphthydrofuryl in neurology]. Ahumada BH Prensa Med Argent; 1971 Jul; 58(21):1067-70. PubMed ID: 5096690 [No Abstract] [Full Text] [Related]
54. [4261 CB tetrazepam trial in a series of 42 patients with hypertonia of different origin]. Boudouresque J; Daniel F Mars Med; 1969; 106(12):1081-5. PubMed ID: 5398400 [No Abstract] [Full Text] [Related]
55. The impact of bromocriptine on blood pressure, heart Rate and noradrenaline concentration after active orthostasis in Parkinson patients. Jost WH; Bellonx AK; Schimrigk K Parkinsonism Relat Disord; 1997 Nov; 3(3):171-2. PubMed ID: 18591072 [No Abstract] [Full Text] [Related]
56. Initial bromocriptine did not change mortality in early, mild Parkinson disease. Albanese A ACP J Club; 2002; 136(3):109. PubMed ID: 11985450 [No Abstract] [Full Text] [Related]
57. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients]. Liaño H; López-Lozano JJ; Ramírez A; Rabes C; Pascual ML Arch Neurobiol (Madr); 1984; 47(3):143-50. PubMed ID: 6508478 [No Abstract] [Full Text] [Related]
58. [Bromocriptine in Parkinson's disease. Personal experience]. Chacón JR; Piqueras L; Pery JM Arch Neurobiol (Madr); 1982; 45(5):371-80. PubMed ID: 7165448 [No Abstract] [Full Text] [Related]
59. [Treatment of Parkinson disease by bromocriptine in the black African]. Ndiaye IP; Jacquin-Cotton L; Martini L Dakar Med; 1980; 25(2):131-5. PubMed ID: 7215100 [No Abstract] [Full Text] [Related]
60. The response of "de novo" Parkinson's disease patients to bromocriptine in a "low and slow" regimen is predictive for prognosis. Sampaio C; Coelho T; Castro-Caldas A; Bastos-Lima A; Levy A J Neural Transm Suppl; 1995; 45():197-202. PubMed ID: 8748626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]